FDA Clears IND for IBI363 in Squamous Non‑Small Cell Lung Cancer
The FDA has cleared an investigational new drug (IND) application for IBI363, a novel PD‑1/IL‑2α‑biased bispecific antibody, as a treatment for those with squamous non‑small cell lung cancer (NSCLC) demonstrating resistance to prior immunotherapy.
The FDA has cleared an investigational new drug (IND) application for IBI363, a novel PD‑1/IL‑2α‑biased bispecific antibody, as a treatment for those with squamous non‑small cell lung cancer (NSCLC) demonstrating resistance to prior immunotherapy.
This clearance allows IBI363 to move into a large Phase 3 trial, potentially providing a new therapeutic option for patients with immunotherapy‑resistant squamous NSCLC, a population that currently has limited treatments.
Bizonyítékszint: Korai humán adat. Kis vagy feltáró emberi adat.
Kapcsolódó jelek
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT